SEARCH

SEARCH BY CITATION

References

  • Ambrosio AL, Dias SM, Polikarpov I, Zurier RB, Burstein SH, Garratt RC (2007). Ajulemic acid, a synthetic nonpsychoactive cannabinoid acid, bound to the ligand binding domain of the human peroxisome proliferator activated receptor gamma. J Biol Chem 282: 1862518633.
  • Astarita G, Di Giacomo B, Gaetani S, Oveisi F, Compton TR, Rivara S et al. (2006). Pharmacological characterization of hydrolysis-resistant analogs of oleoylethanolamide with potent anorexiant properties. J Pharmacol Exp Ther 318: 563570.
  • Auboeuf D, Rieusset J, Fajas L, Vallier P, Frering V, Riou JP et al. (1997). Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 46: 13191327.
  • Barish GD, Narkar VA, Evans RM (2006). PPAR delta: a dagger in the heart of the metabolic syndrome. J Clin Invest 116: 590597.
  • Bishop-Bailey D (2000). Peroxisome proliferator-activated receptors in the cardiovascular system. Br J Pharmacol 129: 823834.
  • Bouaboula M, Hilairet S, Marchand J, Fajas L, Le Fur G, Casellas P (2005). Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation. Eur J Pharmacol 517: 174181.
  • Cimini A, Benedetti E, Cristiano L, Sebastiani P, D'Amico MA, D'Angelo B et al. (2005). Expression of peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors (RXRs) in rat cortical neurons. Neuroscience 130: 325337.
  • Demuth DG, Molleman A (2006). Cannabinoid signalling. Life Sci 78: 549563.
  • Fenner MH, Elstner E (2005). Peroxisome proliferator-activated receptor-gamma ligands for the treatment of breast cancer. Expert Opin Investig Drugs 14: 557568.
  • Ferre P (2004). The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes 53: S43S50.
  • Fievet C, Fruchart JC, Staels B (2006). PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome. Curr Opin Pharmacol 6: 606614.
  • Francis GA, Annicotte JS, Auwerx J (2003). PPAR agonists in the treatment of atherosclerosis. Curr Opin Pharmacol 3: 186191.
  • Fu J, Gaetani S, Oveisi F, Lo Verme J, Serrano A, Rodriguez De Fonseca F et al. (2003). Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 425: 9093.
  • Gasperi V, Fezza F, Pasquariello N, Bari M, Oddi S, Agro AF et al. (2007). Endocannabinoids in adipocytes during differentiation and their role in glucose uptake. Cell Mol Life Sci 64: 219229.
  • Gelman L, Feige JN, Desvergne B (2007). Molecular basis of selective PPARgamma modulation for the treatment of type 2 diabetes. Biochim Biophys Acta; e-pub ahead of print 16 March.
  • Glass CK (2006). Going nuclear in metabolic and cardiovascular disease. J Clin Invest 116: 556560.
  • Guzman M, Lo Verme J, Fu J, Oveisi F, Blazquez C, Piomelli D (2004). Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha). J Biol Chem 279: 2784927854.
  • Hwang J, Kleinhenz DJ, Lassegue B, Griendling KK, Dikalov S, Hart CM (2005). Peroxisome proliferator-activated receptor-gamma ligands regulate endothelial membrane superoxide production. Am J Physiol Cell Physiol 288: C899C905.
  • Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS et al. (1997). Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci USA 94: 43184323.
  • Kozak KR, Crews BC, Morrow JD, Wang LH, Ma YH, Weinander R et al. (2002). 15-Lipoxygenase metabolism of 2-arachidonylglycerol. Generation of a peroxisome proliferator-activated receptor alpha agonist. J Biol Chem 277: 2327823286.
  • Leo A, Galea E, Sastre M (2007). Molecular targets of non-steroidal anti-inflammatory drugs in neurodegenerative diseases. Cell Mol Life Sci 64: 14031418.
  • Liu J, Li H, Burstein SH, Zurier RB, Chen JD (2003). Activation and binding of peroxisome proliferator-activated receptor gamma by synthetic cannabinoid ajulemic acid. Mol Pharmacol 63: 983992.
  • Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A et al. (2005). The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 67: 1519.
  • LoVerme J, Russo R, La Rana G, Fu J, Farthing J, Mattace-Raso G et al. (2006). Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. J Pharmacol Exp Ther 319: 10511061.
  • Matias I, Gonthier MP, Orlando P, Martiadis V, De Petrocellis L, Cervino C et al. (2006). Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 91: 31713180.
  • Moreno S, Farioli-Vecchioli S, Ceru MP (2004). Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience 123: 131145.
  • Mueller E, Drori S, Aiyer A, Yie J, Sarraf P, Chen H et al. (2002). Genetic analysis of adipogenesis through peroxisome proliferator-activated receptor gamma isoforms. J Biol Chem 277: 4192541930.
  • O'Sullivan SE, Bennett AJ, Kendall DA, Randall MD (2006b). Cannabinoids and peroxisome proliferator-activated receptor gamma (PPARγ). Proc Intl Cannabinoid Res Soc (abstract).
  • O'Sullivan SE, Kendall DA, Randall MD (2006a). Further characterization of the time-dependent vascular effects of delta9-tetrahydrocannabinol. J Pharmacol Exp Ther 317: 428438.
  • O'Sullivan SE, Tarling EJ, Bennett AJ, Kendall DA, Randall MD (2005). Novel time-dependent vascular actions of delta9-tetrahydrocannabinol mediated by peroxisome proliferator-activated receptor gamma. Biochem Biophys Res Commun 337: 824831.
  • Randall MD, Kendall DA, Bennett AJ, O'Sullivan SE (2007). Rimonabant in obese patients with type 2 diabetes. Lancet 369: 555.
  • Rangwala SM, Lazar MA (2004). Peroxisome proliferator-activated receptor gamma in diabetes and metabolism. Trends Pharmacol Sci 25: 331336.
  • Rockwell CE, Kaminski NE (2004). A cyclooxygenase metabolite of anandamide causes inhibition of interleukin-2 secretion in murine splenocytes. J Pharmacol Exp Ther 311: 683690.
  • Rockwell CE, Snider NT, Thompson JT, Vanden Heuvel JP, Kaminski NE (2006). Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor gamma independently of cannabinoid receptors 1 and 2. Mol Pharmacol 70: 101111.
  • Rubino T, Forlani G, Vigano D, Zippel R, Parolaro D (2005). Ras/ERK signalling in cannabinoid tolerance: from behaviour to cellular aspects. J Neurochem 93: 984991.
  • Russo R, Loverme J, La Rana G, D'Agostino G, Sasso O, Calignano A et al. (2007). Synergistic antinociception by the cannabinoid receptor agonist anandamide and the PPAR-alpha receptor agonist GW7647. Eur J Pharmacol 566: 117119.
  • Seimandi M, Lemaire G, Pillon A, Perrin A, Carlavan I, Voegel JJ et al. (2005). Differential responses of PPARalpha, PPARdelta, and PPARgamma reporter cell lines to selective PPAR synthetic ligands. Anal Biochem 344: 815.
  • Serrano A, Del Arco I, Javier Pavon F, Macias M, Perez-Valero V, Rodriguez de Fonseca F (2007). The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats. Neuropharmacology; e-pub ahead of print 24 March.
  • Stienstra R, Duval C, M 252 Ller M, Kersten S (2007). PPARs, Obesity, and Inflammation. PPAR Res 95974.
  • Sun Y, Alexander SP, Kendall DA, Bennett AJ (2006). Cannabinoids and PPARalpha signalling. Biochem Soc Trans 34: 10951097.
  • Upham BL, Rummel AM, Carbone JM, Trosko JE, Ouyang Y, Crawford RB et al. (2003). Cannabinoids inhibit gap junctional intercellular communication and activate ERK in a rat liver epithelial cell line. Int J Cancer 104: 1218.
  • Yan ZC, Liu DY, Zhang LL, Shen CY, Ma QL, Cao TB et al. (2007). Exercise reduces adipose tissue via cannabinoid receptor type 1 which is regulated by peroxisome proliferator-activated receptor-delta. Biochem Biophys Res Commun 354: 427433.
  • Yano M, Matsumura T, Senokuchi T, Ishii N, Murata Y, Taketa K et al. (2007). Statins activate peroxisome proliferator-activated receptor gamma through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages. Circ Res 100: 14421451.